logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Capmatinib effective in NSCLC with MET exon 14 skipping mutations

The first approved treatment for people with the mutation was especially effective in previously untreated patients.